SecBot SecBot
8-K ·Filed Apr 9, 2026

IBRX

ImmunityBio, Inc.
BULLISH
Impact 8/10
Horizonimmediate Processed7mo ago SEC0001326110-26-000036
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue beat and sequential growth confirm ANKTIVA's commercial momentum. The fully enrolled pivotal trial de-risks a key regulatory milestone. Traders should monitor the upcoming 10-Q for final numbers and any updates on the BLA submission timeline.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.48
T+0 close · Apr 9, 2026 · via day close
Latest settled
+19.12%
T+60 · $8.91
Vs SPY
+8.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $7.48entry
  2. T+1 · 7mo ago −2.67%α −2.61% · $7.28
  3. T+5 · 7mo ago −3.07%α −6.26% · $7.25
  4. T+20 · 6mo ago +12.03%α +4.46% · $8.38
  5. T+60 · 4mo ago +19.12%α +8.34% · $8.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by continued adoption of ANKTIVA. The company also announced full enrollment in its pivotal BCG-naïve NMIBC trial, with a supplemental BLA submission on track for 2026.

Key Financial Metrics

EPS
−$0.06
est −$0.07 · +14.3%
Revenue
$44.2M
est $43.2M · +2.3% · +168.0% YoY
Rating
beat

Key Facts

  • Preliminary Q1 2026 net product revenue: $44.2 million (168% YoY increase)
  • Q1 2026 revenue represents a 15% sequential increase over Q4 2025 ($38.3M)
  • Full-year 2025 net product revenue was $113 million, a 700% increase over 2024
  • Pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled with IDMC confirming adequate statistical power
  • Supplemental BLA submission for BCG-naïve NMIBC is on track for 2026
  • Cash, cash equivalents, and marketable securities estimated at $380.9 million as of March 31, 2026

Financial Impact

Preliminary Q1 revenue of $44.2M beats consensus of $43.2M and represents a 168% YoY increase

revenuecash

Risk Factors

  • Preliminary financials are subject to final adjustments in the upcoming 10-Q
  • The company continues to report a net loss, though it narrowed in 2025

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326110-26-000036
Document: ibrx-2026498xkexhibit991.htm0001326110-26-000036
Document: 0001326110-26-000036-index-headers.html0001326110-26-000036
Document: 0001326110-26-000036-index.html0001326110-26-000036
Document: 0001326110-26-000036.txt0001326110-26-000036
8-K Data (Synthetic)0001326110-26-000036

US Market Status

Market Closed · Opens Wed (9h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026